MT1H Inhibited Colon Cancer Development via Interacting With DUSP1 and MAPK Signaling Pathway Inactivation

Lijun Jiang1, Xiuqin An1, Yue Li1

  • 1Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.

Insights

Metallothionein 1H (MT1H) inhibits colon cancer (CC) progression by interacting with dual-specificity phosphatase 1 (DUSP1) and deactivating MAPK signaling. This suggests MT1H is a potential therapeutic target for colon cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Colon cancer (CC) remains a significant global health challenge.
  • Metallothionein 1H (MT1H) is a protein whose role in CC progression is not fully understood.
  • Identifying novel therapeutic targets is crucial for improving CC treatment outcomes.

Purpose of the Study:

  • To investigate the impact of MT1H on colon cancer cell proliferation, migration, and invasion.
  • To elucidate the molecular mechanisms underlying MT1H's effects in CC.
  • To explore MT1H as a potential therapeutic target for colon cancer.

Main Methods:

  • Immunohistochemistry (IHC) to assess MT1H expression in human CC tissues.
  • Cell Counting Kit-8 (CCK-8), transwell, and wound healing assays to evaluate CC cell behavior.
  • Western blotting and knockdown experiments to analyze protein interactions and signaling pathways (MAPK, DUSP1).
  • Xenograft mouse models to validate findings in vivo.

Main Results:

  • MT1H was found to be lowly expressed in human CC tissues.
  • Overexpression of MT1H significantly inhibited CC cell proliferation, migration, and invasion in vitro and in vivo.
  • MT1H interacts with and enhances the expression of dual-specificity phosphatase 1 (DUSP1).
  • MT1H-induced inhibition of CC progression was dependent on DUSP1 and involved the suppression of MAPK signaling (ERK, JNK, p38).

Conclusions:

  • MT1H suppresses colon cancer progression by interacting with DUSP1, leading to the deactivation of MAPK signaling.
  • MT1H acts as a tumor suppressor in colon cancer.
  • MT1H represents a promising novel therapeutic target for colon cancer treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K